Cogent Biosciences, Inc. (COGT) closed the last trading session at $5.13, gaining 12% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $16.64 indicates a 224.4% upside potential.The average comprises 11 short-term price targets ranging from a low of $7 to a high of $24, with a standard deviation of $5.28. While the lowest estimate indicates an increase of 36.5% from the current pric ...

Drug Development - Bezuclastinib is being developed for Non-Advanced Systemic Mastocytosis (Non-AdvSM), Advanced Systemic Mastocytosis (AdvSM), and gastrointestinal stromal tumors (GIST) with FDA orphan drug designation granted for Mastocytosis[78]. - The SUMMIT trial for Non-AdvSM completed enrollment in Q3 2023 with 54 patients, and Part 2 completed enrollment in Q4 2024 with 179 patients, with top-line results expected in July 2025[80]. - In the SUMMIT trial, 89% of patients achieved >50% decrease in serum tryptase by week 4, and 95% achieved serum tryptase levels <20 ng/ml by week 24[83]. - The APEX trial for AdvSM completed enrollment in Q1 2025 with 58 patients, and top-line results are expected in the second half of 2025[86]. - In the APEX trial, an objective response rate (ORR) of 52% was achieved, with 94% of patients showing a ≥50% reduction in serum tryptase levels[88][89]. - The PEAK trial for GIST enrolled 413 patients, with top-line results expected by the end of 2025; the median progression-free survival (mPFS) was 10.2 months in all patients[92]. - The combination of bezuclastinib and sunitinib resulted in a disease control rate of 80% in all patients and 100% in second-line patients with prior imatinib only[93]. Financial Performance - The company reported a net loss of $72.0 million for the three months ended March 31, 2025, compared to a net loss of $58.3 million for the same period in 2024, with an accumulated deficit of $931.5 million as of March 31, 2025[102]. - Total operating expenses for the three months ended March 31, 2025, were $74.9 million, an increase of $12.5 million compared to $62.4 million in the same period of 2024[120]. - Research and development expenses increased by $10.3 million to $63.0 million for the three months ended March 31, 2025, driven by the development of bezuclastinib and early-stage programs[121]. - General and administrative expenses rose to $11.9 million for the three months ended March 31, 2025, compared to $9.7 million in 2024, primarily due to higher personnel costs[122]. - Net loss for the three months ended March 31, 2025, was $72.0 million, compared to a net loss of $58.3 million in the same period of 2024, reflecting an increase of $13.7 million[120]. - Net cash used in operating activities for the three months ended March 31, 2025, was $66.5 million, compared to $52.5 million in 2024[131]. - Net cash provided by financing activities was $25.0 million for the three months ended March 31, 2025, compared to $214.1 million in the same period of 2024[135]. Funding and Financial Strategy - The company has cash, cash equivalents, and marketable securities totaling $245.7 million, expected to fund operations through late 2026[106]. - The company expects to require additional funding to support ongoing research and development programs[138]. - The company has established a strategy to finance operations through equity offerings, debt financings, and collaborations, as it does not expect to generate revenue from product sales in the near term[104]. - The company has U.S. federal and state net operating loss carryforwards of $268.1 million and $128.7 million, respectively, which may offset future taxable income[116]. - The company has recorded a full valuation allowance against its net deferred tax assets at each balance sheet date[118]. Intellectual Property - The company has an exclusive license agreement with Plexxikon Inc. with potential milestone payments totaling up to $32.5 million based on clinical and regulatory achievements[96]. - The patent protection for bezuclastinib extends through 2033, with potential extensions through a new patent application filed in 2023 for the optimized formulation[96]. Research and Development Pipeline - The company is actively enrolling patients in a Phase 1 study of CGT4859, targeting tumors with FGFR2 and FGFR3 mutations, including advanced cholangiocarcinoma[97]. - CGT4255 demonstrated low nM potency against ErbB2 wild-type and oncogenic mutations with over 100-fold selectivity over wild-type EGFR, and complete regressions were observed at a dose of 100 mg/kg[99]. - CGT6297, a PI3Kα inhibitor, showed >95% inhibition of pAKT in a H1047R PD model, with superior efficacy compared to alpelisib in tumor growth inhibition models[100]. - The company is developing a potent KRAS inhibitor, CGT9109, which demonstrated >90% pERK inhibition and robust tumor regression in KRASG12D tumor-bearing mouse models[101]. - The company plans to submit an IND application for CGT4255 in 2025 and for CGT6297 in the same year[99][100]. - The company anticipates significant increases in research and development expenses due to ongoing clinical and preclinical activities[109].

Exhibit 99.1 Cogent Biosciences Reports First Quarter 2025 Financial Results Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in cash, suf icient to fund operations into late 2026 WALTHAM, Mass. and BOULDER, Colo., May 6, 2025 – Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on develo ...

WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from four pipeline programs during poster sessions at the American Association for Cancer Research (AACR) 2025 Annual Meeting taking place in Chicago. “We welcome the opportunity to present updated results from these programs that represent our exciting pipeline of po ...

WALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at the upcoming 2025 AACR Annual Meeting being held in Chicago, IL April 25-30, 2025. Poster Details Title: Identification of a potent KRAS (ON) inhibitor with selectivity for mutant KRAS over HRAS and NRASSession Category: ChemistrySession Title: ...

One stock that might be an intriguing choice for investors right now is Cogent Biosciences, Inc. (COGT) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably tak ...

WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Leerink Healthcare Conference on Wednesday, March 12, 2025 at 10:00 a.m. ET. A live webcast will be available on the Investors & Media page of Cogent's website at investors.cogentbio.com. A replay of the webcast will be available approximatel ...

65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (NASDAQ:COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced expanded clinical results from the Open Label Extension (OLE) portion ...

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 https://files.reportify.cc/m Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 Bezuclastinib – Gastrointestinal Stromal Tumors (GIST) • Report top-line results by the end of 2025 from the pivotal Phase 3 PEAK trial. PEAK is a global, blinded, randomized clinical trial studying the combination of bezuclastinib and sunitinib versus sunitinib alone in patients with ...